Synriam Dt
Synriam Dt Uses, Dosage, Side Effects, Food Interaction and all others data.
Piperaquine is an antimalarial agent first synthesized in the 1960's and used throughout China . Its use declined in the 1980's as piperaquine resistant strains of Plasmodium falciparum appeared and artemisinin derivatives became available. It has come back into use in combination with the artemisinin derivative Artenimol as part of the combination product Eurartesim . Eurartesim was first authorized for market by the European Medicines Agency in October 2011.
Piperaquine inhibits the P. Falciparum parasite's haem detoxification pathway .
| Trade Name | Synriam Dt |
| Generic | Piperaquine + Arterolane |
| Type | Tablet |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | India |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
For the treatment of uncomplicated Plasmodium falciparum infection in adults, children, and infants aged 6 months and up weighing over 5 kg . Used in combination with Artenimol.
Synriam Dt is also used to associated treatment for these conditions: Malaria caused by Plasmodium falciparum
How Synriam Dt works
The mechanism of piperaquine inhibition of the haem detoxification pathway is unknown but is expected to be similar to that of Chloroquine.
Toxicity
Studies of piperaquine in monkeys and dogs have shown some hepatotoxicity and reversible depression in white blood cells and neutrophils . Additional observations include infiltration of macrophages with intracytoplasmic basophilic granular material consistent with phospholipidosis and degenerative lesions in numerous organs and tissues. These effects were seen at exposure levels similar to clinical dosing in humans. At high doses, piperaquine can interfere with cardiac conduction and produce effects on blood pressure. Mild phototoxicity has been observed with piperaquine in rats exposed to UV light.
Volume of Distribution
Piperaquine is thought to distribute into a central compartment with an apparent volume of 26.7 L/kg, and two peripheral compartments with apparent volumes of 76.8 L/kg and 617 L/kg . These combine for a total volume of distribution of 720.5 L/kg.
Elimination Route
Piperaquine is slowly absorbed and exhibits multiple peaks in its plasma concentration curve suggestive of enterohepatic recycling occurring alongside the absorption process . Due to this complication there is no discreet value for bioavailability but piperaquine is highly absorbed into systemic circulation. When taken with food, Cmax increases by 217% and mean exposure increases by 177%. Tmax is not affected by food and remains around 5 h . Piperaquine has been observed to accumulate more in females to a degree of 30-50% more than males . It also collects in red blood cells similar to Artenimol.
Half Life
The terminal elimination half-life was observed to be 576h or 24 days . This is thought to be due to the extensive distribution of piperaquine.
Clearance
The mean apparent total clearance has been observed to be 1.12 L/h/kg in adult malaria patients .
Elimination Route
Piperaquine is mainly excreted in the feces with a negligible amount in the urine .
Innovators Monograph
You find simplified version here Synriam Dt
